#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	13178	16S	1529	1529	99.87	16S.l6.c4.ctg.1	2639	615.8	0	.	n	.	0	A69G	SNP	69	69	A	630	630	G	802	G,A,C	797,2,2	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	13178	16S	1529	1529	99.87	16S.l6.c4.ctg.1	2639	615.8	0	.	n	.	0	C1450T	SNP	1450	1450	C	2011	2011	T	816	T,G	814,2	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	13178	16S	1529	1529	99.87	16S.l6.c4.ctg.1	2639	615.8	1	SNP	n	C1184T	0	.	.	1184	1184	C	1745	1745	C	822	C,T,G	820,1,1	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	13178	16S	1529	1529	99.87	16S.l6.c4.ctg.1	2639	615.8	0	HET	.	.	.	G28A,C	.	28	28	G	589	589	G	756	G,A,C	585,169,2	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	22592	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3966	708.7	0	.	n	.	0	G1337A	SNP	1337	1337	G	1877	1877	A	954	A,G,C	949,2,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	22592	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3966	708.7	0	.	n	.	0	T1971C	SNP	1971	1971	T	2511	2511	C	748	C,G	747,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	22592	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3966	708.7	1	SNP	n	A2045G	0	.	.	2045	2045	A	2585	2585	A	747	A,G	746,1	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	22592	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3966	708.7	1	SNP	n	C2597T	0	.	.	2597	2597	C	3137	3137	C	799	C,T,G,A	791,4,3,1	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
folP.WHO_F_01537c	folP.WHO_F_01537c	1	1	27	2050	folP	852	852	100.0	folP.l15.c4.ctg.1	2071	123.1	1	SNP	p	R228S	0	.	.	682	684	CGC	1227	1229	CGC	202;201;202	C;G;C	202;201;202	folP.WHO_F_01537c:1:1:R228S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	5352	gyrA	2751	2751	100.0	gyrA.l15.c17.ctg.1	3851	172.7	1	SNP	p	S91F	0	.	.	271	273	TCC	822	824	TCC	184;183;182	T,G;C;C	183,1;183;182	gyrA.WHO_F_00668c:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	5352	gyrA	2751	2751	100.0	gyrA.l15.c17.ctg.1	3851	172.7	1	SNP	p	D95G	0	.	.	283	285	GAC	834	836	GAC	183;185;183	G;A;C	183;185;183	gyrA.WHO_F_00668c:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	5352	gyrA	2751	2751	100.0	gyrA.l15.c17.ctg.1	3851	172.7	1	SNP	p	D95N	0	.	.	283	285	GAC	834	836	GAC	183;185;183	G;A;C	183;185;183	gyrA.WHO_F_00668c:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
mtrR.WHO_O_01438	mtrR.WHO_O_01438	1	1	539	1908	mtrR	633	633	99.21	mtrR.l15.c4.ctg.1	1793	132.8	0	.	p	.	0	A39T	NONSYN	115	117	GCC	689	691	ACC	205;208;208	A,C;C,A;C	204,1;207,1;208	.	.
mtrR.WHO_O_01438	mtrR.WHO_O_01438	1	1	539	1908	mtrR	633	633	99.21	mtrR.l15.c4.ctg.1	1793	132.8	1	SNP	p	G45D	1	G45D	NONSYN	133	135	GGC	707	709	GAC	210;211;211	G;A,T;C	210;210,1;211	mtrR.WHO_O_01438:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR.WHO_O_01438	mtrR.WHO_O_01438	1	1	539	1908	mtrR	633	633	99.21	mtrR.l15.c4.ctg.1	1793	132.8	0	.	p	.	0	Y105H	NONSYN	313	315	TAC	887	889	CAC	248;248;250	C,A;A;C	247,1;248;250	.	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	19	1172	mtrR_promoter	250	250	100.0	mtrR_promoter.l15.c17.ctg.1	1454	100.0	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
parC.WHO_V_00204c	parC.WHO_V_00204c	1	1	27	4932	parC	2304	2304	99.83	parC.l15.c4.ctg.1	3578	171.9	1	SNP	p	D86N	0	.	.	256	258	GAC	884	886	GAC	217;219;218	G,C;A,C;C	216,1;217,1;217	parC.WHO_V_00204c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_V_00204c	parC.WHO_V_00204c	1	1	27	4932	parC	2304	2304	99.83	parC.l15.c4.ctg.1	3578	171.9	1	SNP	p	S88P	0	.	.	262	264	TCC	890	892	TCC	217;221;224	T,C;C;C,T,G,A	216,1;221;221,1,1,1	parC.WHO_V_00204c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	4206	parE	1986	1986	99.95	parE.l15.c4.ctg.1	3060	170.8	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1776	1778	GGC	235;236;234	G,A;G;C	234,1;235;233	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.9.001	penA.9.001	1	1	27	3648	penA	1749	1749	99.94	penA.l6.c4.ctg.1	2867	158.6	1	SNP	p	A311V	0	.	.	931	933	GCA	1471	1473	GCA	191;195;194	G,A,C;C,T;A	189,1,1;194,1;194	penA.9.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	3648	penA	1749	1749	99.94	penA.l6.c4.ctg.1	2867	158.6	1	SNP	p	I312M	0	.	.	934	936	ATC	1474	1476	ATC	194;197;196	A;T,C;C,A	194;196,1;195,1	penA.9.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	3648	penA	1749	1749	99.94	penA.l6.c4.ctg.1	2867	158.6	1	SNP	p	V316P	0	.	.	946	948	GTG	1486	1488	GTG	208;209;210	G,A;T;G	207,1;209;210	penA.9.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	3648	penA	1749	1749	99.94	penA.l6.c4.ctg.1	2867	158.6	1	SNP	p	V316T	0	.	.	946	948	GTG	1486	1488	GTG	208;209;210	G,A;T;G	207,1;209;210	penA.9.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	3648	penA	1749	1749	99.94	penA.l6.c4.ctg.1	2867	158.6	1	SNP	p	T484S	0	.	.	1450	1452	ACC	1990	1992	ACC	226;227;226	A;C;C	226;227;226	penA.9.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	3648	penA	1749	1749	99.94	penA.l6.c4.ctg.1	2867	158.6	1	SNP	p	A502V	0	.	.	1504	1506	GCG	2044	2046	GCG	211;212;211	G;C;G,T,A	211;212;209,1,1	penA.9.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	3648	penA	1749	1749	99.94	penA.l6.c4.ctg.1	2867	158.6	1	SNP	p	A502P	0	.	.	1504	1506	GCG	2044	2046	GCG	211;212;211	G;C;G,T,A	211;212;209,1,1	penA.9.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	3648	penA	1749	1749	99.94	penA.l6.c4.ctg.1	2867	158.6	1	SNP	p	G543S	0	.	.	1627	1629	GGC	2167	2169	GGC	194;194;194	G,A;G;C,G	193,1;194;193,1	penA.9.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	3648	penA	1749	1749	99.94	penA.l6.c4.ctg.1	2867	158.6	1	SNP	p	G546S	0	.	.	1636	1638	GGC	2176	2178	GGC	190;191;193	G,T;G;C,T,G	189,1;191;191,1,1	penA.9.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	3648	penA	1749	1749	99.94	penA.l6.c4.ctg.1	2867	158.6	1	SNP	p	L552S	0	.	.	1654	1656	CTG	2194	2196	CTG	183;184;184	C;T,G;G,A	183;183,1;183,1	penA.9.001:1:1:L552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	5054	ponA	2397	2397	99.96	ponA.l15.c17.ctg.1	3490	180.3	1	SNP	p	L421P	1	.	.	1261	1263	CCG	1781	1783	CCG	202;201;199	C,A;C,A;G	201,1;200,1;199	ponA.WHO_G_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	2646	porA	1146	1146	99.65	porA.l15.c4.ctg.1	2352	140.3	0	.	p	.	0	M83fs	FSHIFT	247	247	A	848	848	C	205	C	205	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	280	porB1a	984	226	90.71	porB1a.l6.c4.ctg.3	501	21.6	0	.	p	.	0	V258L	NONSYN	772	774	GTA	133	135	TTA	23;25;28	T;T;A	23;25;28	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	280	porB1a	984	226	90.71	porB1a.l6.c4.ctg.3	501	21.6	0	.	p	.	0	Y273H	NONSYN	817	819	TAT	178	180	CAT	59;59;59	C;A;T	59;59;59	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	280	porB1a	984	226	90.71	porB1a.l6.c4.ctg.3	501	21.6	0	.	p	.	0	D274S	NONSYN	820	822	GAT	181	183	AGT	59;59;59	A;G;T	59;59;59	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	280	porB1a	984	226	90.71	porB1a.l6.c4.ctg.3	501	21.6	0	.	p	.	0	N277Y	NONSYN	829	831	AAC	190	192	TAC	59;59;59	T;A;C	59;59;59	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	280	porB1a	984	226	90.71	porB1a.l6.c4.ctg.3	501	21.6	0	.	p	.	0	R307E	NONSYN	919	921	AGA	280	282	GAA	2;2;2	G;A;A	2;2;2	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	280	porB1a	984	226	90.71	porB1a.l6.c4.ctg.3	501	21.6	0	.	p	.	0	T311A	NONSYN	931	933	ACA	292	294	GCA	4;4;4	G;C;A	4;4;4	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	280	porB1a	984	226	90.71	porB1a.l6.c4.ctg.3	501	21.6	0	.	p	.	0	F314I	NONSYN	940	942	TTC	301	303	ATC	4;4;4	A;T;C	4;4;4	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	280	porB1a	984	226	90.71	porB1a.l6.c4.ctg.3	501	21.6	0	.	p	.	0	A316S	NONSYN	946	948	GCG	307	309	TCG	4;4;4	T;C;G	4;4;4	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	280	porB1a	984	226	90.71	porB1a.l6.c4.ctg.3	501	21.6	0	.	p	.	0	V318A	NONSYN	952	954	GTC	313	315	GCC	4;4;4	G;C;C	4;4;4	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	280	porB1a	984	226	90.71	porB1a.l6.c4.ctg.3	501	21.6	0	.	p	.	0	G319S	NONSYN	955	957	GGC	316	318	AGC	4;4;4	A;G;C	4;4;4	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	280	porB1a	984	226	90.71	porB1a.l6.c4.ctg.3	501	21.6	0	.	p	.	0	G320A	NONSYN	958	960	GGT	319	321	GCC	4;4;4	G;C;C	4;4;4	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	280	porB1a	984	226	90.71	porB1a.l6.c4.ctg.3	501	21.6	0	.	p	.	0	G322V	NONSYN	964	966	GGT	325	327	GTT	5;5;5	G;T;T	5;5;5	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2706	porB1b	1035	1035	98.38	porB1b.l15.c30.ctg.1	1660	201.3	0	.	p	.	0	R143G	NONSYN	427	429	AGA	870	872	GGA	206;206;206	G,T;G;A,T,G	205,1;206;204,1,1	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2706	porB1b	1035	1035	98.38	porB1b.l15.c30.ctg.1	1660	201.3	0	.	p	.	0	Y211fs	FSHIFT	631	631	T	1074	1074	T	237	T	237	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2706	porB1b	1035	1035	98.38	porB1b.l15.c30.ctg.1	1660	201.3	1	SNP	p	G120K	0	.	.	358	360	GGT	801	803	GGT	220;218;218	G,A;G;T	219,1;218;218	porB1b.WHO_U_02278c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2706	porB1b	1035	1035	98.38	porB1b.l15.c30.ctg.1	1660	201.3	1	SNP	p	A121D	0	.	.	361	363	GCC	804	806	GCC	217;217;215	G,A;C,T;C,A	216,1;216,1;214,1	porB1b.WHO_U_02278c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2706	porB1b	1035	1035	98.38	porB1b.l15.c30.ctg.1	1660	201.3	1	SNP	p	A121N	0	.	.	361	363	GCC	804	806	GCC	217;217;215	G,A;C,T;C,A	216,1;216,1;214,1	porB1b.WHO_U_02278c:1:1:A121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_F_02153c	rpoB.WHO_F_02153c	1	1	27	8484	rpoB	4179	4179	100.0	rpoB.l15.c4.ctg.1	5297	199.4	1	SNP	p	H553N	0	.	.	1657	1659	CAT	2275	2277	CAT	199;201;202	C,A,T;A;T,G	197,1,1;201;201,1	rpoB.WHO_F_02153c:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	1228	rpsJ	312	312	100.0	rpsJ.l15.c4.ctg.1	1547	98.7	1	SNP	p	V57M	1	.	.	169	171	ATG	736	738	ATG	216;215;211	A;T,C;G	216;214,1;211	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
